ArticleFrontiers in pediatrics2023
Exposure to proton pump inhibitors is associated with the development of pediatric autoimmune diseases.
Article in Frontiers in pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07036627 (Evaluation of the Intestinal Microbiota in Pediatric Patients Treated With Proton Pump Inhibitors), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Intestinal Microbiota in Pediatric Patients Treated With Proton Pump Inhibitors: A Prospective Longitudinal Study
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Coordinated oral-gut microbiota relocation in connective tissue diseases: a systematic review.Frontiers in immunology · 2026Pooled it
- Why think twice before prescribing proton pump inhibitors.European journal of pediatrics · 2025Review
- Safety of Proton Pump Inhibitors in Pediatric Population: A Systematic Review.Global pediatric health · 2024Review
- Acid-suppressive medication and incidence of chronic childhood immune-mediated diseases: A scoping review.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proton pump inhibitors (PPIs) have been associated with decreased gut microbiota diversity. Disrupted gut microbiota composition has been reported in several autoimmune diseases (ADs), such as type 1 diabetes mellitus (DM), autoimmune thyroiditis (AIT), juvenile idiopathic arthritis (JIA), and inflammatory bowel diseases (IBD). We investigated whether PPIs are associated with the development of ADs in children and concluded that PPI exposures could be related to the onset of ADs, especially IBD and potentially AIT as well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.